Alector Inc
About
Alector Inc (NASDAQ:ALEC) — investor relations, events, news, and company updates on 6ix.
Latest News
Yesterday
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
Feb 25 2026
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Feb 24 2026
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
Dec 12 2025
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
Dec 1 2025
Alector to Participate in the Bank of America CNS Therapeutics Conference
Financials
Revenue
$21.05 M
Market Cap
$265.97 M
EPS
-1.39